Krystal Biotech, Inc. 10-Q

ITEM 4. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s “disclosure controls and procedures” (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15. Changes in Internal Control over Financial Reporting During the second quarter of 2023, we completed the implementation of the inventory module within our enterprise resource planning software, Microsoft Dynamics D365 (“Dynamics”), as part of our plan to upgrade our systems and processes as we prepared for the commercial launch of VYJUVEK. We expect the implementation of this additional module to strengthen our internal controls by automating a number of accounting and reporting controls supporting our manufacturing, inventory and commercial processes. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve. Other than discussed above, no change in our internal control over financial reporting occurred during the quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 33 PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS The information set forth under the heading “Legal Proceedings” in Note 6 of the notes to condensed consolidated financial statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.